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A B S T R A C T
Background
One of the most feared symptoms associated with cancer is pain. Opioids remain the mainstay of pain treatment but corticosteroids are
often used concurrently as co- or adjuvant analgesics. Due to their anti-inflammatory mechanism of action, corticosteroids are said to
provide effective analgesia for pain associated with inflammation and in the management of cancer-related complications such as brain
metastasis and spinal cord compression. However, corticosteroids have a wide range of adverse effects that are dose and time dependent.
Objectives
To evaluate the efficacy of corticosteroids in treating cancer-related pain in adults.
Search methods
We searched theCochraneCentral Register ofControlledTrials (CENTRAL2014, Issue 4),MEDLINE (OVID) (1966 to29 September
2014), EMBASE (OVID) (1970 to 29 September 2014), CINAHL (1982 to 29 September 2014), Science Citation Index (Web of
Science) (1899 to 29 September 2014) and Conference Proceedings Citation Index - Science (Web of Science) (1990 to 29 September
2014).
Selection criteria
Any randomised or prospective controlled trial that included patients over 18 years with cancer-related pain were eligible for the review.
Corticosteroids were compared to placebo or usual treatment and/or supportive care.
Data collection and analysis
All review authors independently assessed trial quality and extracted data. We used arithmetic means and standard deviations for each
outcome to report the mean difference (MD) with 95% confidence interval (CI).
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Main results
Fifteen studies met the inclusion criteria, enrolling 1926 participants. The trial size varied from 20 to 598 patients. Most studies
compared corticosteroids, particularly dexamethasone, to standard therapy. We included six studies with data at one week in the meta-
analysis for pain intensity; no data were available at that time point for the remaining studies. Corticosteroid therapy resulted in less
pain (measured on a scale of 0 to 10 with a lower score indicating less pain) compared to control at one week (MD 0.84 lower pain, 95%
CI 1.38 to 0.30 lower; low quality evidence). Adverse events were poorly documented. Factors limiting statistical analysis included the
lack of standardised measurements of pain and the use of different agents, dosages, comparisons and routes of drug delivery. Subgroup
analysis according to type of cancer was not possible. The quality of this evidence was limited by the risk of bias of the studies and
small sample size. The results were also compromised by attrition, with data missing for the enrolled patients.
Authors’ conclusions
The evidence for the efficacy of corticosteroids for pain control in cancer patients is weak. Significant pain relief was noted in some
studies, albeit only for a short period of time. This could be important for patients with poor clinical status. Further trials, with increased
numbers of participants, are needed to evaluate the safety and effectiveness of corticosteroids for the management cancer pain in adults,
and to establish an ideal dose, duration of therapy and route of administration.
P L A I N L A N G U A G E S U M M A R Y
Corticosteroids for the management of cancer pain in adults
Background: One of the most feared symptoms associated with cancer is pain. Opioids remain the mainstay of pain treatment but
corticosteroids are often used at the same time, along with standard pain relievers. This review evaluates the clinical trial evidence up
to 29 September 2014 to determine how effective corticosteroids are in treating cancer-related pain in adults and how well tolerated
this treatment is for these patients.
Study characteristics: We found 15 relevant studies with 1926 participants. The trial size varied from 20 to 598 patients and the duration
of the included studies ranged from seven days to 42 weeks. Most studies compared corticosteroids, particularly dexamethasone, to
standard therapy.
Key results and quality of the evidence: Overall, we found that the current evidence is based on studies that contain only a small number
of patients. The following conclusions can be made from the available evidence: 1) the evidence for the efficacy of corticosteroids for
pain control in cancer patients is weak (GRADE quality of evidence for pain outcome was low); 2) significant pain relief was noted in
some studies, albeit only for a short period of time; this could be important for patients who have only a short time to live; 3) overall,
more studies found corticosteroids not to be of benefit; 4) it was not possible to determine whether steroids are more effective for pain
in specific cancers; and 5) the side effect profile of steroids, especially in the longer term, is not well described.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Corticosteroids for cancer-related pain in adults
Patient or population: adult patients with cancer-related pain
Settings: in- and out-patients
Intervention: corticosteroids
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control Corticosteroids
Pain at 1 week
Scale from: 0 to 10
The mean pain at 1 week
in the control group was
3.77
The mean pain at 1 week
in the intervention groups
was
0.84 lower
(1.38 to 0.3 lower)
315
(6 studies)
⊕⊕©©
low1
Pain (1 to 10) with lower
score indicating less pain
Quality of evidence low
due to the small num-
ber of participants in each
arm for the included stud-
ies
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1We downgraded the quality of evidence by two levels from high to low because of likely selection bias and the small number of patients
in the included studies.
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B A C K G R O U N D
Description of the condition
Cancer remains the leading cause of death worldwide. Over 12
million new cases are diagnosed each year (Foley 2011). The dis-
ease carries significant morbidity. Pain resulting directly or indi-
rectly from the abnormal growth of malignant cells in normal
tissue is the most common and most feared symptom associated
with cancer (Van den Beuken-van Everdingen 2007). It is esti-
mated that one-third of cancer patients on active therapy, and two-
thirds of those with advanced disease, experience pain that requires
treatment with analgesic drugs (Foley 2011). Of concern, there is
also considerable evidence that cancer pain is often under treated
(Foley 2011). While opioids remain the mainstay of treatment for
cancer pain, co-analgesics or adjuvants are often used concurrently
to optimise pain control. Corticosteroids (steroids) are commonly
used in this context.
Description of the intervention
Steroids are essential for maintaining homeostasis and regulating a
wide variety of physiological processes in the human body (Busillo
2013). Therapeutically, they are widely prescribed for the treat-
ment of inflammation, auto-immune disorders and malignancies
(Busillo 2013). They are commonly used in the management of
cancer pain.
How the intervention might work
Corticosteroids are used for relief of pain associated with space-
occupying lesions, not only in the brain, spinal cord and nerves,
but also in the liver and soft tissues (eTG Complete 2014). They
are usedwhere theremay be inflammation and oedema in confined
spaces, including intracerebral, pelvic, retroperitoneal and spinal
malignant disease, and are often used as an interim measure while
awaiting more definitive therapies such as radiotherapy (eTG
Complete 2014).
Corticosteroids have been proposed to have effects on all four
stages of pain nociception including transduction, transmission,
modulation and pain perception, although the exact mechanisms
remain unclear (Leppert 2012). The anti-inflammatory effect of
corticosteroids may be due to (i) inhibition of the expression of
collagenase, an enzyme involved in tissue degeneration during in-
flammatory mechanisms, (ii) inhibition of pro-inflammatory cy-
tokines, which have been implicated in a number of pain states, or
(iii) by stimulating the synthesis of lipocortin, which in turn blocks
the production of eicosanoids (Leppert 2012; Paulsen 2013).
It is proposed that the mechanism of pain relief for cancer-related
neuropathic pain is by the inhibition of prostaglandin production,
reduction of inflammation thus decreasing capillary permeability
and reducing oedema (Pharo 2005)
In summary, the mechanism of action of corticosteroids in the
reduction of cancer pain remains unclear.
Why it is important to do this review
Corticosteroids are prescribed frequently in oncology practice to
reduce swelling and pain caused by cancer and may also be used
to control and prevent nausea and vomiting caused by chemo-
therapy. In addition, it is common in palliative care practice, espe-
cially for patients with advanced malignant disease, for a variety of
symptom control indications including pain, nausea, mood eleva-
tion, anorexia and fatigue (Farr 1990; Hardy 2001; Riechelmann
2007). This is despite the fact that steroids are associated with
significant side effects, especially following long-term use (Hanks
2009). There is little objective evidence in the literature to sup-
port the use of corticosteroids for symptom control, and concerns
have been raised about the ’uncontrolled’ use of steroids in cancer
patients (Gannon 2002; Twycross 1985). Patients who are started
on steroids in the palliative care setting are often not closely mon-
itored, allowing for the development of debilitating side effects,
often in the context of limited clinical benefit. Some of these side
effects include: proximal myopathy, oral candidiasis, symptomatic
hyperglycaemia, psychological disturbances, gastrointestinal irri-
tation, increased susceptibility to infections and the development
of osteoporosis. For example, although steroids are frequently ad-
ministered to assist with mood elevation, some studies have shown
that corticosteroid therapy may result in more disturbing side ef-
fects such as insomnia, delirium, depression, anxiety and psychosis
(Vyvey 2010). There is a relevant gap in the body of knowledge,
in that most patients with cancer will be prescribed steroids at
some stage during their disease course with very little evidence of
effectiveness.
O B J E C T I V E S
To evaluate the efficacy of corticosteroids in treating cancer-related
pain in adults.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Any randomised controlled or prospective controlled trial.
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Types of participants
Participants with cancer-related pain, aged 18 years and above.
Types of interventions
Types of interventions included any corticosteroid used to treat
cancer-related pain.
We considered all routes of drug administration.
Comparisons were:
• placebo;
• no intervention;
• usual treatment or supportive care; or
• non-pharmacological treatment for pain.
Types of outcome measures
Primary outcomes
• Patient-reported pain intensity and pain relief using
validated scales (visual analogue scale (VAS), verbal rating scale
(VRS), numerical rating scale (NRS)).
Secondary outcomes
• Adverse events
• Quality of life
• Patient satisfaction
• Other relevant outcome measures, e.g. cost-effectiveness
data
Search methods for identification of studies
The search strategy attempted to identify as many trials as possible
that met the inclusion criteria without limitation by language,
publication type or status or by date.
Electronic searches
We searched the following electronic databases:
1. the Cochrane Central Register of Controlled Trials
(CENTRAL 2014, Issue 4);
2. MEDLINE (OVID) (1966 to 29 September 2014);
3. EMBASE (OVID) (1970 to 29 September 2014);
4. CINAHL (1982 to 29/ September 2014);
5. Science Citation Index (Web of Science) (1899 to 29
September 2014);
6. Conference Proceedings Citation Index - Science (Web of
Science) (1990 to 29 September 2014).
The MEDLINE search strategy was adapted by a Librarian (KR)
from one originally devised by the Trials Search Co-ordinator of
the Cochrane Pain, Palliative and Supportive Care Review Group.
The Cochrane Highly Sensitive Search Strategy (CHSS) filter for
identifying randomised trials in MEDLINE via OVID was also
modified and applied.This searchwas adapted andmodified across
the other databases. The search strategies are shown in Appendices
1 to 4 (Appendix 1; Appendix 2; Appendix 3; Appendix 4).
Searching other resources
We checked the bibliographic references of any relevant identi-
fied studies in order to find additional trials not identified by
the electronic searches. We also searched www.ClinicalTrials.gov,
the metaRegister of Controlled Trials (mRCT www.controlled-
trials.com/mrct/), and the World Health Organization (WHO)
International Clinical Trials Registry Platform (ICTRP) (
apps.who.int/trialsearch/) to identify any ongoing trials. In
order to identify any unpublished or grey literature, we
searched the Internet using the Google Scholar search engine (
www.googlescholar.com),with selected terms from the above strat-
egy. If only the abstract was published, we attempted to contact
the authors for further details or for the unpublished paper. The
searches were conducted by one of the review authors (KR) who
is a Librarian. All searches were current as of 29 September 2014.
Data collection and analysis
Selection of studies
Four of the review authors (JH, PG, SJ-M, KR) independently
assessed the titles and abstracts of all the studies identified by the
search for potential inclusion. Each of these authors independently
selected all potentially relevant studies for inclusion by apply-
ing the selection criteria outlined in the ’Criteria for considering
studies for this review’ section. We then compared these four lists,
discussed any differences and either included or excluded the pa-
pers based on a majority decision.
A PRISMA study flow diagram (Liberati 2009) is included in
Figure 1 to document the screening process, as recommended in
Part 2, Section 11.2.1 of the Cochrane Handbook for Systematic
Reviews of Interventions (Higgins 2011).
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Figure 1. PRISMA Study flow diagram.
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Data extraction and management
Four review authors (AL, AH, SK, SJ-M) independently extracted
data from the studies, using a piloted data extraction form.Data ex-
tracted included information about the year of study, study design,
number of participants treated, participant demographic details,
type of cancer, drug and dosing regimen, study design (placebo
or active control) and methods, study duration and follow-up,
outcome measures (measurement of pain, pain scale), withdrawals
and adverse events. We resolved potential disagreements by dis-
cussion.
Assessment of risk of bias in included studies
Six of the authors (AL, AH, JH, PG, SK, KR) independently
assessed the risk of bias of each of the included studies by using
the ’Risk of bias’ assessment method outlined in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
We resolved potential disagreements by discussion. For each study
we assessed the risk of bias for the following domains.
1. Random sequence generation (checking for selection bias).
2. Allocation concealment (checking for selection bias).
3. Blinding of participants and personnel (checking for
performance bias).
4. Blinding of outcome assessment (checking for detection
bias).
5. Incomplete outcome data (checking for attrition bias).
6. Selective reporting (checking for reporting bias).
7. Size of study (checking for possible biases confounded by
small size). We assessed studies as being at low risk of bias (200
or more participants per treatment arm); unclear risk of bias (50
to 199 participants per treatment arm); or high risk of bias
(fewer than 50 participants per treatment arm).
We used the GRADE approach to assess the overall quality of
the evidence for the primary outcome, with downgrading of the
evidence from ’high quality’ by one level for serious (or by two
for very serious) study limitations (risk of bias), indirectness of
evidence, serious inconsistency, imprecision of effect estimates or
potential publication bias (Langendam 2013). The outcome in-
cluded in the ’Summary of findings’ table was pain at week one
(Summary of findings for the main comparison).
Measures of treatment effect
For continuous outcomes between groups, we measured arith-
metic means and standard deviations (SD) and reported the mean
difference (MD) with 95% CI. When an outcome was derived
with different instruments measuring the same construct, we used
the standardised mean difference (SMD) with 95% CIs.
Unit of analysis issues
We only included studies in which randomisation was by the in-
dividual patient; this included cross-over or n = 1 studies.
Dealing with missing data
In cases where data were missing, we attempted to contact the
authors to request the missing data. This strategy did not result in
any additional data. We ascertained the method of assessing data
processed from withdrawals where possible. It was not possible to
assess the impact of missing data in sensitivity analyses due to the
low study numbers. In all cases we aimed to perform intention-
to-treat analyses.
Assessment of heterogeneity
There may be an effect of differences between patients, environ-
ment (inpatient versus outpatient) and outcome measures. We as-
sessed heterogeneity by using the I2 statistic. We considered I2
values above 50% to represent substantial heterogeneity, in line
withHiggins 2011, and assessed potential sources of heterogeneity
through subgroup analyses.
Assessment of reporting biases
We interpreted the results of tests in the light of visual inspection
of the funnel plot. If there was evidence of small study effects, we
considered publication bias as only one of a number of possible
explanations (Higgins 2011).
Data synthesis
We entered the data extracted from the included studies into Re-
view Manager (RevMan 2014), which we used for data synthesis.
Where appropriate, we pooled data for each dichotomous out-
come and calculated RRs with 95% CIs using a random-effects
model.
Sensitivity analysis
When sufficient data were available, we examined the robustness
of the meta-analyses by conducting sensitivity analyses using dif-
ferent components of the ’Risk of bias’ assessment, particularly
those relating to whether allocation concealment and patient/as-
sessor blinding were adequate. We conducted further sensitivity
analyses to examine the impact of missing data on the results as a
large proportion of the studies are at an ’unknown’ or ’high’ risk of
attrition bias and, finally, sensitivity analyses to examine whether
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publication status and trial size influenced the results. Unfortu-
nately, due to the low number of studies within each comparison,
we were unable to perform any sensitivity analyses.
R E S U L T S
Description of studies
See: ’Characteristics of included studies’ and ’Characteristics of
excluded studies’ tables.
Results of the search
The PRISMA diagram (Figure 1) outlines the number of records
identified in the search and the screening process for these papers.
In the initial database search we identified 5891 records. Of these,
743 were duplicates and we rejected 5107 based on information
given in the title and abstract.
We identified 41 publications for full-text retrieval. We excluded
26 of these studies during screening. In three studies, only the ab-
stract had been published and, as further detail was unavailable, we
excluded them. Seven studies did not satisfy the inclusion criteria
andwe excluded 16 because painwas not an endpoint. The reasons
for exclusion of each study are described in the ’Characteristics
of excluded studies’ table. A total of 15 studies met the inclu-
sion criteria for this review. These included six placebo-controlled
studies, one placebo-controlled cross-over study, five studies with
active controls, one open-label and two low-dose versus high-dose
studies (Table 1). We evaluated the results of six trials relative
to pain intensity at one week (Basile 2012; Bruera 1985; Bruera
2004; Mercadante 2007; Paulsen 2014; Yennurajalingam 2013).
The other trials could not be included in the meta-analysis due to
missing data at this time point.
Included studies
We identified 15 studies meeting the inclusion criteria (Basile
2012; Bruera 1985; Bruera 2004;Della 1989; Fossa 2001;Graham
2006; Lauretti 2013; Lee 2008; Mercadante 2007; Paulsen
2014; Popiela 1989; Teshima 1996; Twycross 1985; Vecht 1989;
Yennurajalingam 2013). The 15 studies included 1926 enrolled
participants. Trial size varied from 20 to 598 participants.
A detailed description of the included studies can be found in the
’Characteristics of included studies’ table.
Primary disease sites
The primary disease sites addressed are tabulated in Table 2.
Most of the trials did not include patients with a specific cancer
type, with the exception of Fossa 2001, Lee 2008 and Teshima
1996.
Types of studies
Studies were included in which steroids were used as part of a
treatment regimen and pain was assessed as an outcome (Fossa
2001; Lee 2008). Two studies tested high-dose versus low-dose
steroids (Graham 2006; Vecht 1989).
Pain requirement as an entry criteria
Eight of the 15 studies required that participants had pain at study
entry (Basile 2012; Della 1989; Lauretti 2013; Mercadante 2007;
Paulsen 2014; Popiela 1989; Teshima 1996; Yennurajalingam
2013).
Pain as primary endpoint
Of the 15 included studies, only nine trialswere designedwith pain
relief as a primary outcome measure (Basile 2012; Bruera 1985;
Graham 2006; Lauretti 2013; Mercadante 2007; Paulsen 2014;
Teshima 1996; Twycross 1985; Vecht 1989). Of the remainder,
six studies were designed to describe differences in chronic nausea,
cancer-related fatigue and quality of life (Bruera 2004;Della 1989;
Fossa 2001; Lee 2008; Popiela 1989; Yennurajalingam 2013).
Types of corticosteroids studied
Dexamethasone was used in eight studies (Basile 2012; Bruera
2004; Graham 2006; Lauretti 2013; Lee 2008; Mercadante 2007;
Vecht 1989; Yennurajalingam 2013), methylprednisolone in five
studies (Bruera 1985; Della 1989; Paulsen 2014; Popiela 1989;
Teshima 1996), and prednisone (Fossa 2001) and prednisolone
(Twycross 1985) in one study each (Table 1).
Dexamethasone was administered orally in three studies (Bruera
2004; Mercadante 2007; Yennurajalingam 2013), and intra-
venously in five studies (Basile 2012; Graham 2006; Lauretti
2013; Lee 2008; Vecht 1989). Methylprednisolone was used in
five trials, administered orally in two studies (Bruera 1985; Paulsen
2014), and intravenously in three studies (Della 1989; Popiela
1989; Teshima 1996). Prednisone (Fossa 2001) and prednisolone
(Twycross 1985) were administered orally in both studies.
Additional details of dosage are provided in Table 3.
Pain and analgesic measurement tools
Different measurement tools were used to measure pain intensity.
• Visual analogue scale 0 to 10 (four studies) (Basile 2012;
Graham 2006; Lauretti 2013; Vecht 1989)
• Visual analogue scale 0 to 100 (two studies) (Bruera 1985;
Twycross 1985)
• Numerical scale 0 to 10 (six studies) (Bruera 2004; Della
1989; Mercadante 2007; Paulsen 2014; Popiela 1989;
Yennurajalingam 2013)
• Quality of life questionnaire including pain (two studies)
(Fossa 2001; Lee 2008)
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• Radiation Therapy Oncology Group (RTOG) pain scale
(one study) (Teshima 1996)
Excluded studies
We excluded 26 studies (Campio 1983; Chanan-Khan 2011;
Coloma 2001;Datta 1997;Dutta 2012; Friedenberg 1991; Fuccio
2011; Gomez-Hernandez 2010; Hird 2009; Laval 2000; North
2003; Richardson 2009; Richardson 2010; Richardson 2011;
Richardson 2012; Rinehart 2010; Rizzo 2009; Sanguineti 2003;
Schmuth 2002; Tantawy 2008; Tong 1982; Vecht 1994; Vij
2012; Yennurajalingam 2010; Yennurajalingam 2012; Yoshioka
2011). Reasons for exclusion are provided in the ’Characteristics
of excluded studies’ table.
Risk of bias in included studies
We assessed each study using the Cochrane ’Risk of bias’ tool.
Overall findings are presented in the ’Risk of bias’ graph (Figure
2), which reviews the authors’ judgements about each risk of bias
item presented as percentages across all included studies. Authors’
judgements about each risk of bias for each included study is shown
in ’Risk of bias’ summary (Figure 3).
Figure 2. ’Risk of bias’ graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. ’Risk of bias’ summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
All studies reported that they were randomised, but only six out
of 15 properly described the method used to generate the random
sequence. Four studies were randomised using a computer pro-
gram (Della 1989; Lauretti 2013; Paulsen 2014; Popiela 1989).
The participants from Graham 2006 were randomised using the
Superdex website. Those from Teshima 1996 were randomly al-
located according to Peto’s balanced randomised list. We judged
the six studies describing randomisation to have low risk and the
other nine to have unclear risk of bias.
We judged seven studies to be low risk for allocation concealment;
the trial medications were of identical appearance (Bruera 2004;
Paulsen 2014), the packages were blinded (Della 1989; Lauretti
2013; Popiela 1989; Vecht 1989), or they used a password pro-
tected website to maintain blinding (Graham 2006). Two trials
were at high risk, being open-label or not placebo-controlled (Lee
2008; Mercadante 2007). The remaining six trials were of unclear
risk as not enough information was provided on the method of
allocation concealment.
Blinding
Ten trials were at low risk, reporting blinding of patients
and personnel (Basile 2012; Bruera 1985; Bruera 2004; Della
1989; Paulsen 2014; Popiela 1989; Twycross 1985; Vecht 1989;
Yennurajalingam 2013). In five studies blinding was not possible
due to different dosage intervals, because physicians were provided
with patient’s assigned treatment or because it was an open-label
trial, so we assessed them as having high risk (Fossa 2001; Graham
2006; Lee 2008; Mercadante 2007; Teshima 1996).
The outcome assessment was blind in eight trials, judged to
have low risk (Bruera 1985; Bruera 2004; Della 1989; Paulsen
2014; Popiela 1989;Twycross 1985;Vecht1989; Yennurajalingam
2013). In the other three trials it was unclear whether the outcome
assessor was blinded or not (Basile 2012; Fossa 2001; Lauretti
2013). In four studies the outcome assessment was not blind be-
cause physicians were provided with the patient’s assigned treat-
ment, it was an open-label study or there was no placebo given
(Graham 2006; Lee 2008; Mercadante 2007; Teshima 1996).
These studies are at high risk of bias.
Incomplete outcome data
It was not certain whether Lauretti 2013 reported all the out-
comes that had been assessed, but in seven trials it appeared that
additional pertinent outcomes should have been reported and
their omission left a gap in the evidence (Bruera 1985; Fossa
2001;Graham2006; Lee 2008;Mercadante 2007;Twycross 1985;
Yennurajalingam 2013). We assessed these seven studies to have a
high risk of bias. The remaining seven trials appear to have reported
all relevant outcomes related to the subject matter (Basile 2012;
Bruera 2004; Della 1989; Paulsen 2014; Popiela 1989; Teshima
1996; Vecht 1989).
Selective reporting
In two studies it was unclear if there was a reporting bias (Fossa
2001;Mercadante 2007).We found a high risk in Bruera 1985 and
Teshima 1996, as some data evaluating pain and adverse events
were not mentioned. In 11 trials, judged to be low risk, no report-
ing gaps were detected (Basile 2012; Bruera 2004; Della 1989;
Graham 2006; Lauretti 2013; Lee 2008; Paulsen 2014; Popiela
1989; Twycross 1985; Vecht 1989; Yennurajalingam 2013).
Other potential sources of bias
Sample size was an issue. Small studies are thought to be at in-
creased risk of bias as they are unlikely to be adequately powered.
We considered only one of the studies large enough to give a low
risk of bias (more than 200 patients per arm) (Lee 2008). We
judged four studies to have an unclear risk of bias due to sample
size (50 to 199 participants per arm) (Della 1989; Fossa 2001;
Popiela 1989; Yennurajalingam 2013). We judged the remaining
10 trials to have a high risk of bias because of their small number
of participants (Basile 2012; Bruera 1985; Bruera 2004; Graham
2006; Lauretti 2013; Mercadante 2007; Paulsen 2014; Teshima
1996; Twycross 1985; Vecht 1989).
Effects of interventions
See: Summary of findings for the main comparison
Corticosteroids for cancer-related pain in adults
Primary outcome
Patient-reported pain intensity and pain relief using
validated scales
For the meta-analysis, only those studies that provided mean pain
intensity and the standard deviation at oneweek could be included.
In this case, we evaluated six studies relative to pain intensity (Basile
2012; Bruera 1985; Bruera 2004;Mercadante 2007; Paulsen2014;
Yennurajalingam 2013). The other trials could not be included
in the meta-analysis due to missing data. Data were reported for
baseline and after one week of intervention.
A total of 372 patients at baseline and 315 patients after one week
of interventionwere involved in these six studies. After oneweek of
intervention, the intervention armwas favoured in all trials (Figure
11Corticosteroids for the management of cancer-related pain in adults (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
4). The total mean difference is -0.84 with a 95% confidence
interval of -1.38 to -0.30 (Analysis 1.1).While the study by Bruera
1985 was a cross-over trial, inclusion in the meta-analysis did not
affect the overall review findings.
Figure 4. Forest plot of pain at 1 week.
Secondary outcomes
A meta-analysis for secondary outcomes could not be undertaken
as the data were heterogeneous with no consistency of measure-
ment tools or outcome measures. Patient satisfaction and cost-ef-
fectiveness data was not available.
Adverse events
Not all studies included information on adverse events and sev-
eral reported no or only minimal adverse events compared to
controls or placebo (Bruera 2004; Graham 2006; Lauretti 2013;
Mercadante 2007; Yennurajalingam 2013). The most common
adverse events attributed to steroids were restlessness and sleep-
lessness (Paulsen 2014), gastrointestinal and cardiovascular events
(Popiela 1989), Cushingoid facies, anxiety, fluid retention (Bruera
1985), hypocalcaemia and hyperglycaemia (Della 1989). In the
latter study, more patients randomised to steroids dropped out
because of toxicity.
Quality of life/patient well-being
Four studies reported on quality of life (Bruera 1985; Bruera
2004; Mercadante 2007; Yennurajalingam 2013). Quality of life
or patient well-being improved in three of four studies (Bruera
1985; Mercadante 2007; Yennurajalingam 2013).
D I S C U S S I O N
Summary of main results
The objective of this systematic review was to assess whether cor-
ticosteroids are effective in reducing cancer-related pain. Fifteen
randomised controlled trials with 1926 enrolled participants were
included; six placebo-controlled studies, one placebo-controlled
cross-over study, five studies with active controls, one open-label
study and two low-dose versus high-dose studies. Included studies
assessed either dexamethasone (at doses of 8 mg and 20 mg in an
oral tablet or 4 mg/ml, 10 mg, 16 mg, 40 mg, 96 mg and 100
mg intravenously), methylprednisolone (16 mg and 32 mg orally
or 125 mg and 500 mg intravenously) or prednisone 15 mg or
prednisolone 20 mg orally.
For the meta-analysis only six studies could be evaluated for pain
intensity. Data were reported after one week of intervention, since
this was the only time that could be standardised across all six trials.
The following conclusion regarding the effectiveness of corticos-
teroids for pain relief in cancer patients should be interpreted with
consideration of the small number of eligible studies. The quality
of studies was generally poor with a high risk of bias identified.
• There is some evidence to suggest that there is a benefit in
favour of the use of corticosteroids (mean difference (MD) -0.84,
95% confidence interval (CI) -1.38 to -0.30) for cancer pain for
up to one week of intervention. However, it is debatable if the
reduction of a mean pain score of 0.8 with wide confidence
intervals is clinically meaningful.
• There were insufficient data to evaluate different subgroups
such as drug type, route of administration, dosage and different
primary disease types.
Further trials with increased numbers of participants are needed
to evaluate the safety and effectiveness of corticosteroids for the
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management cancer pain in adults, and to establish an ideal dose,
duration of therapy and route of administration.
Overall completeness and applicability of
evidence
We identified 15 studies that met the inclusion criteria, but in-
cluded only six studies in the meta-analysis for pain intensity with
insufficient data available for the remaining studies.
We did not attempt to classify specific pain syndromes. There were
insufficient data for subgroup analyses.
Statistical analysis in relation to pain intensity in this review was
limited by a number of factors. There is a lack of standardised mea-
surement of pain. Several different tools have been used for pain
measurement. In the meta-analysis, visual analogue scale scores (0
to 10) and numerical scale scores (0 to 10) were compared.
The results are also influenced by differences in steroid type,
dosage, comparators, routes of administration, primary disease
type, aetiology of pain and heterogeneity of study populations.
One of the studies had a single dose of intravenous dexametha-
sone as an intervention compared to multiple oral doses of dex-
amethasone or methylprednisolone. Comparators included in the
meta-analysis included both “standard treatment” (two studies)
and placebo (four studies). Trials where dexamethasone was used
primarily as an anticancer treatment rather than as a co-analgesic
were also included.
Reporting of data
Basile 2012 reported clear data for pain outcomes at baseline and
after one week of intervention. Adverse events were not reported.
Bruera 1985 tabulated the intensity of pain (VAS), adverse events
and quality of life in each group at baseline and after one week of
intervention.
Bruera 2004 presented mean pain scores, intensity of nausea and
fatigue, as well as quality of life scores for both patient groups.
Della 1989 presented graphical representation of mean change
from baseline in Nurses’ Observation Scale for Inpatient Evalua-
tion (NOSIE) and linear analogue scale assessment (LASA) total
score. No standard deviation was provided.
Fossa 2001 presented data in the form of graphs. No original data
were presented and it was therefore not possible to include this
trial in the meta-analysis.
Graham 2006 published graphical representation of pain scores.
Standard deviations were missing and therefore the trial could not
be included in the meta-analysis.
Lauretti 2013 was not included in the meta-analysis as data on
measured pain scores were not presented.
Lee 2008 had missing data on mean pain intensity and standard
deviation. The study was not included in the meta-analysis.
Mercadante 2007 tabulated the mean scores and 95% CI for pain
intensity, intensity of nausea, fatigue, drowsiness and also quality
of life scores.
Paulsen 2014 reported clear data for pain outcomes, fatigue and
appetite at baseline and after one week of intervention.
Popiela 1989 published a graphical representation of adverse
events and quality of life. No data were presented on pain inten-
sity scores, therefore the study could not be included in the meta-
analysis.
Teshima 1996 presented pain scores and quality of life in a graph-
ical field, but no standard deviation was provided. The trial was
not included in the meta-analysis.
Twycross 1985 tabulated pain intensity scores. These could not
be included in the meta-analysis as only the difference in outcome
was reported at day eight with no baseline data available.
Vecht 1989 presented average pain scores and standard deviation
assessed by a numerical rating scale in graphical form. No original
data were presented and therefore it was not possible to include it
in the meta-analysis.
Yennurajalingam 2013 presented the mean and standard devia-
tion of pain intensity, nausea, depression, fatigue, drowsiness and
quality of life.
Quality of the evidence
The quality of the evidence was low. This is due to imprecision
(likely selection bias and the small number of patients) in the in-
cluded studies. Nine studies did not adequately describe sequence
generation and one study did not provide information about al-
location concealment. In five studies the blinding of participants
and personnel was not provided and in four studies the outcome
assessment was not blinded. In a number of studies it appeared
that additional pertinent outcomes should have been reported and
in two studies a risk of bias in selective reporting was identified.
Sample size was of concern. Only one study had more than 200
participants in each arm. Ten studies had fewer than 50 partici-
pants in each arm.
Potential biases in the review process
Data extraction, including ’Risk of bias’ assessment, was done
independently by all authors to minimise bias. The conclusion
that can be drawn is limited by the number and the quality of
the included studies. Several trials were susceptible to bias and
hampered by incomplete outcome data and small sample size.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
The evidence of the efficacy of corticosteroids for pain control in
cancer patients is weak. Our meta-analysis of studies with data
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at one week suggests that corticosteroids may relieve cancer pain,
even if only for a short period of time. However, it is debatable if
the reduction of a mean pain score of 0.8 with wide confidence
intervals is clinically meaningful. In addition, any evidence of the
efficacy of corticosteroids in the reduction of cancer pain must be
weighed up against the associated significant side effects. Further-
more, we can make no recommendation regarding type of steroid,
dose, route of delivery, side effect profile or treatment period.
In light of the above, we recommend that clinicians are cautious
in their prescribing of steroids for pain management, that they
assess benefit carefully, treat for the shortest possible time and
discontinue early in the absence of symptom relief.
Implications for research
Further trials with increased numbers of participants are needed to
evaluate the safety and effectiveness of corticosteroids for theman-
agement cancer pain in adults, and to establish an ideal dose, du-
ration of therapy and route of administration. Further adequately
powered randomised controlled trials with pain as a primary out-
come, measured with universally accepted standardised tools, us-
ing a single agent (dexamethasone), at a pre-specified dose and
route over a short time period are indicated. Longer-term toxicity
should be documented during a follow-up period.
A C K N OW L E D G E M E N T S
The authors acknowledge the support of Eve Pinkerton in the ini-
tial phase of this project and the staff of the University of Queens-
land Library.
Cochrane Review Group funding acknowledgement: The Na-
tional Institute for Health Research (NIHR) is the largest single
funder of the Cochrane PaPaS Group. Disclaimer: The views and
opinions expressed therein are those of the authors and do not
necessarily reflect those of the NIHR, National Health Service
(NHS) or the Department of Health.
R E F E R E N C E S
References to studies included in this review
Basile 2012 {published and unpublished data}
Basile A, Masala S, Banna G, Cotta E, Cavalli M,
Fiumara P, et al. Intrasomatic injection of corticosteroid
followed by vertebroplasty increases early pain relief rather
than vertebroplasty alone in vertebral bone neoplasms:
preliminary experience. Skeletal Radiology 2012;41(4):
459–64.
Bruera 1985 {published and unpublished data}
Bruera E, Roca E, Cedaro L. Action of oral
methylprednisolone in terminal cancer patients: a
prospective randomized double-blind study. Cancer
Treatment Reports 1985;69(7-8):751–4.
Bruera 2004 {published and unpublished data}
Bruera E, Moyano JR, Sala R, Rico MA, Bosnjak S,
Bertolino M, et al. Dexamethasone in addition to
metoclopramide for chronic nausea in patients with
advanced cancer: a randomized controlled trial. Journal of
Pain and Symptom Management 2004;28(4):381–8.
Della 1989 {published and unpublished data}
Della Cuna GR, Pellegrini A, Piazzi M. Effect of
methylprednisolone sodium succinate on quality of life
in preterminal cancer patients: a placebo-controlled,
multicenter study. The Methylprednisolone Preterminal
Cancer Study Group. European Journal of Cancer & Clinical
Oncology 1989;25(12):1817–21.
Fossa 2001 {published and unpublished data}
Fossa SD, Slee PH, Brausi M, Horenblas S, Hall RR,
Hetherington JW, et al. Flutamide versus prednisone in
patients with prostate cancer symptomatically progressing
after androgen-ablative therapy: a phase III study of the
European organization for research and treatment of cancer
genitourinary group. Journal of Clinical Oncology 2001;19
(1):62–71.
Graham 2006 {published and unpublished data}
Graham PH, Capp A, Dalaney G, Goozee G, Hickey
B, Turner S, et al. A pilot randomised comparison of
dexamethasone 96 mg vs 16 mg per day for malignant
spinal-cord compression treated by radiotherapy: TROG
01.05 Superdex study. Clinical Oncology 2006;18(1):70–6.
Lauretti 2013 {published and unpublished data}
Lauretti GR, Rizzo CC, Mattos AL, Rodrigues SW. Epidural
methadone results in dose-dependent analgesia in cancer
pain, further enhanced by epidural dexamethasone. British
Journal of Cancer 2013;108(2):259–64.
Lee 2008 {published and unpublished data}
Lee SJ, Richardson PG, Sonneveld P, Schuster MW, Irwin
D, San Miguel JF, et al. Bortezomib is associated with better
health-related quality of life than high-dose dexamethasone
in patients with relapsed multiple myeloma: results from
the APEX study. British Journal of Haematology 2008;143
(4):511–9.
Mercadante 2007 {published and unpublished data}
Mercadante SL, Berchovich M, Casuccio A, Fulfaro
F, Mangione S. A prospective randomized study of
corticosteroids as adjuvant drugs to opioids in advanced
cancer patients. American Journal of Hospice and Palliative
Medicine 2007;24(1):13–9.
Paulsen 2014 {published data only}
Paulsen Ø, Klepstad P, Rosland JH, et al. Efficacy of
methylprednisolone on pain, fatigue, and appetite loss in
14Corticosteroids for the management of cancer-related pain in adults (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
patients with advanced cancer using opioids: a randomized,
placebo-controlled, double-blind trial. Journal of Clinical
Oncology 2014;32(29):3221–8.
Popiela 1989 {published and unpublished data}
Popiela T, Lucchi R, Giongo F. Methylprednisolone as
palliative therapy for female terminal cancer patients. The
Methylprednisolone Female Preterminal Cancer Study
Group. European Journal of Cancer & Clinical Oncology
1989;25(12):1823–9.
Teshima 1996 {published and unpublished data}
Teshima T, Inoue T, Ikeda H, Murayama S, Yamazaki
H, Ohtani M, et al. Symptomatic relief for patients
with osseous metastasis treated with radiation and
methylpredonisolone: a prospective randomized study.
Radiation Medicine - Medical Imaging and Radiation
Oncology 1996;14(4):185–8.
Twycross 1985 {published and unpublished data}
Twycross RG, Guppy D. Prednisolone in terminal breast
and bronchogenic cancer. Practitioner 1985;229(1399):
57–9.
Vecht 1989 {published and unpublished data}
Vecht CJ, Haaxma-Reiche H, Van Putten WLJ, de Visser
M, Vries EP, Twijnstra A. Initial bolus of conventional
versus high-dose dexamethasone in metastatic spinal cord
compression. Neurology 1989;39(9):1255–7.
Yennurajalingam 2013 {published and unpublished data}
Yennurajalingam S, Frisbee-Hume S, Palmer JL, Delgado-
Guay MO, Bull J, Phan AT, et al. Reduction of cancer-
related fatigue with dexamethasone: a double-blind,
randomized, placebo-controlled trial in patients with
advanced cancer. Journal of Clinical Oncology 2013;31(25):
3076–82.
References to studies excluded from this review
Campio 1983 {published data only}
Campio L, Hearron AE. Comparison of 6-
methylprednisolone (6-MP) and placebo in improvement of
the quality of life in pre-terminal cancer patients [abstract].
Journal of Steroid Biochemistry 1983;19 Suppl:92.
Chanan-Khan 2011 {published data only}
Chanan-Khan A, Miller KC, Lawrence D, Padmanabhan S,
Miller A, Hernandez-Illatazurri F, et al. Tumor flare reaction
associated with lenalidomide treatment in patients with
chronic lymphocytic leukaemia predicts clinical response.
Cancer 2011;117(10):2127–35.
Coloma 2001 {published data only}
Coloma M, Duffy LL, White PF, Kendall Tongier W, Huber
PJ Jr. Dexamethasone facilitates discharge after outpatient
anorectal surgery. Anesthesia and Analgesia 2001;92(1):
85–8.
Datta 1997 {published data only}
Datta SN, Thomas K, Matthews PN. Is prednisolone
as good as flutamide in hormone refractory metastatic
carcinoma of the prostate?. Journal of Urology 1997;158(1):
175–7.
Dutta 2012 {published data only}
Dutta S, Sharma S, Gupta A, et al. Topical mometasone
furoate (0.1%)-An effective prophylaxis for prevention
of radiation dermatitis: A prospective randomized study.
Journal of Cancer Research and Therapeutics 2012;8:175.
Friedenberg 1991 {published data only}
Friedenberg WR, Kyle RA, Knospe WH, Bennett JM,
Tsiatis AA, Oken MM. High-dose dexamethasone for
refractory or relapsing multiple myeloma. American Journal
of Hematology 1991;36(3):171–5.
Fuccio 2011 {published data only}
Fuccio L, Guido A, Laterza L, Eusebi LH, Busutti L,
Bunkheila F, et al. Randomised clinical trial: preventive
treatment with topical rectal beclomethasone dipropionate
reduces post-radiation risk of bleeding in patients irradiated
for prostate cancer. Alimentary Pharmacology & Therapeutics
2011;34(6):628–37.
Gomez-Hernandez 2010 {published data only}
Gomez-Hernandez J, Orozco-Alatorre AL, Dominguez-
Contreras M, Oceguera-Villanueva A, Gómez-Romo S,
Alvarez Villaseñor AS, et al. Preoperative dexamethasone
reduces postoperative pain, nausea and vomiting following
mastectomy for breast cancer. BMC Cancer 2010;10:692.
Hird 2009 {published data only}
Hird A, Zhang L, Holt T, Fairchild A, DeAngelis C,
Loblaw A, et al. Dexamethasone for the prophylaxis of
radiation-induced pain flare after palliative radiotherapy for
symptomatic bone metastases: a phase II study. Clinical
Oncology (Royal College of Radiologists) 2009;21(4):329–35.
Laval 2000 {published data only}
Laval G, Girardier J, Lassaunire JM, Leduc B, Haond C,
Schaerer R. The use of steroids in the management of
inoperable intestinal obstruction in terminal cancer patients:
do they remove the obstruction?. Palliative Medicine 2000;
14(1):3–10.
North 2003 {published data only}
North SA, Au H, Halls SB, Tkachuk L, Mackey JR. A
randomized, phase III, double-blind, placebo-controlled
trial of intrapleural instillation of methylprednisolone
acetate in the management of malignant pleural effusion.
Chest 2003;123(3):822–7.
Richardson 2009 {published data only}
Richardson PG, Weller E, Jagannath S, Avigan DE, Alsina
M, Schlossman RL, et al. Multicenter, phase I, dose-
escalation trial of lenalidomide plus bortezomib for relapsed
and relapsed/refractory multiple myeloma. Journal of
Clinical Oncology 2009;27(34):5713–9.
Richardson 2010 {published data only}
Richardson PG, Siegel D, Baz R, et al. A Phase 1/2 multi-
center, randomized, open label dose escalation study to
determine the maximum tolerated dose, safety, and efficacy
of pomalidomide alone or in combination with low-dose
dexamethasone in patients with relapsed and refractory
multiple myeloma who have received prior treatment that
includes lenalidomide and bortezomib. Blood, ASH Annual
Meeting Abstracts 2010;116:Abstract 864.
15Corticosteroids for the management of cancer-related pain in adults (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Richardson 2011 {published data only}
Richardson PG, Siegel DS, Vij R, et al. Randomized, open
label phase 1/2 study of pomalidomide (POM) alone or
in combination with low-Dose Dexamethasone (LoDex)
in patients (Pts) with relapsed and refractory multiple
myeloma who have received prior treatment that includes
lenalidomide (LEN) and bortezomib (BORT): Phase 2
results. Blood 2011;118:Abstract 634.
Richardson 2012 {published data only}
Richardson PG, Jakubowiak A, Bahlis NJ, et al. Treatment
outcomes with pomalidomide (POM) in combination
with low-dose dexamethasone (LODEX) in patients with
relapsed and refractory multiple myeloma (RRMM) and del
(17p13) and/or t(4;14)(p16;q32) cytogenetic abnormalities
who have received prior therapy with lenalidomide (LEN)
and bortezomib (BORT). Blood 2012;120:Abstract 4053.
Rinehart 2010 {published data only}
Rinehart JJ, Arnold SM, Kloecker GH, et al. Randomized
phase II trial of carboplatin (C) and gemcitabine (G) with
or without dexamethasone (Dex) in patients (pts) with stage
IV non-small cell lung cancer (NSCLC). Journal of Clinical
Oncology 2010;28(15):9150.
Rizzo 2009 {published data only}
Rizzo CC, Lauretti GR, Mattos AL. The combination of
epidural methadone and dexamethasone for cancer pain.
European Journal of Pain 2009;13:258.
Sanguineti 2003 {published data only}
Sanguineti G, Franzone P, Marcenaro M, Foppiano F, Vitale
V. Sucralfate versus mesalazine versus hydrocortisone in the
prevention of acute radiation proctitis during conformal
radiotherapy for prostate carcinoma. A randomized study.
Strahlentherapie und Onkologie 2003;179(7):464–70.
Schmuth 2002 {published data only}
Schmuth M, Wimmer MA, Hofer S, Sztankay A, Weinlich
G, Linder DM, et al. Topical corticosteroid therapy for
acute radiation dermatitis: a prospective, randomized,
double-blind study. British Journal of Dermatology 2002;
146(6):983–91.
Tantawy 2008 {published data only}
Tantawy AGM, El-Samahy KA, Omran AF. Effect of
dexamethasone addition to epidural morphine on pain, and
morphine-related side effects after pelvic oncologic surgery.
Egyptian Journal of Anaesthesia 2008;24(1):75–80.
Tong 1982 {published data only}
Tong D, Gillick L, Hendrickson FR. The palliation of
symptomatic osseous metastases. Final results of the study
by the Radiation Therapy Oncology Group. Cancer 1982;
50(5):893–9.
Vecht 1994 {published data only}
Vecht CJ, Hovestadt A, Verbiest HBC, van Vliet JJ, van
Putten WL. Dose-effect relationship of dexamethasone
on Karnofsky performance in metastatic brain tumors: a
randomized study of doses of 4, 8, and 16 mg per day.
Neurology 1994;44(4):675–80.
Vij 2012 {published data only}
Vij R, Hofmeister CC, Richardson PG, et al. Pomalidomide
(POM) with low-dose dexamethasone (LODEX) in patients
with relapsed and refractory multiple myeloma (RRMM):
Outcomes based on prior treatment exposure. Blood 2012;
120:Abstract: 4070.
Yennurajalingam 2010 {published data only}
Yennurajalingam S, Palmer JL, Reuben JM, et al. The effect
of dexamethasone on symptom burden in patients with
advanced cancer. Journal of Clinical Oncology 2010;28(15s):
Abstract: TPS318.
Yennurajalingam 2012 {published data only}
Yennurajalingam S, Susan FH, Marvin ODG, et al.
Dexamethasone (DM) for cancer-related fatigue: A double-
blinded, randomized, placebo-controlled trial. Journal of
Clinical Oncology 2012;30(Suppl):Abstract 9002.
Yoshioka 2011 {published data only}
Yoshioka H, Mio T, Nakatani K, et al. Randomized phase II
trial of gemcitabine and carboplatin (G/C) with or without
dexamethasone (DEX) pretreatment in chemotherapy-naive
patients (pts) with advanced non-small cell lung cancer
(NSCLC) - Results of kyoto thoracic oncology research
group (KTORG) trial 0501. European Journal of Cancer
2011;47:625.
Additional references
Busillo 2013
Busillo JM, Cidlowski JA. The five Rs of glucocorticoid
action during inflammation: ready, reinforce, repress,
resolve, and restore. Trends in Endocrinology and Metabolism
2013;24(3):109–19.
eTG Complete 2014
Therapeutic Guidelines Ltd. Corticosteroids: use in pain
management and palliative care. Therapeutic Guidelines:
eTG Complete [electronic resource]. North Melbourne:
Therapeutic Guidelines Limited, 2014.
Farr 1990
Farr WC. The use of corticosteroids for symptom
management in terminally ill patients. American Journal of
Hospice and Palliative Care 1990;7:41.
Foley 2011
Foley MK. How well is cancer pain treated?. Palliative
Medicine 2011;25(5):398–401.
Gannon 2002
Gannon C, McNamara P. A retrospective observation of
corticosteroid use at the end of life in a hospice. Journal of
Pain and Symptom Management 2002;24(3):328–34.
Hanks 2009
Hanks G, Cherny N, Christakis N, Fallon M, Kaasa S,
Portenoy R (editors). Oxford Textbook of Palliative Care. 4th
Edition. Oxford Press, 2009.
Hardy 2001
Hardy J, Rees E, Ling J, Stone P, Burman R, Feuer D, et
al. A prospective survey of the use of dexamethasone on a
palliative care unit. Palliative Medicine 2001;15:3–8.
16Corticosteroids for the management of cancer-related pain in adults (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Higgins 2011
Higgins JPT, Altman DG (editors). Chapter 8: Assessing
risk of bias in included studies. In: Higgins JPT, Green
S (editors). Cochrane Handbook for Systematic Reviews
of Interventions Version 5.1.0 [updated March 2011].
The Cochrane Collaboration, 2011. Available from
www.cochrane-handbook.org.
Langendam 2013
Langendam MW, Akl EA, Dahm P, Glasziou P, Guyatt G,
Schünemann HJ. Assessing and presenting summaries of
evidence in Cochrane Reviews. Systematic Reviews 2013;2:
81–9.
Leppert 2012
Leppert W, Buss T. The role of corticosteroids in the
treatment of pain in cancer patients. Current Pain and
Headache Reports 2012;16:307–13.
Liberati 2009
Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC,
Ioannidis JPA, et al. The PRISMA statement for reporting
systematic reviews and meta-analyses of studies that evaluate
health care interventions: explanation and elaboration.
Annals of Internal Medicine 2009;151(4):W65–W94.
[DOI: 10.7326/0003-4819-151-4-200908180-00136]
Paulsen 2013
Paulsen O, Aass N, Kaasa S, Dale O. Do corticosteroids
provide analgesic effects in cancer patients? A systematic
review. Journal of Pain and Symptom Management 2013;46:
96–105.
Pharo 2005
Pharo GH, Zhou L. Pharmacologic management of cancer
pain. Journal of the American Osteopathic Association 2005;
105(11 Suppl 5):S21–8.
RevMan 2014
The Nordic Cochrane Centre, The Cochrane Collaboration.
Review Manager (RevMan). 5.3. Copenhagen: The Nordic
Cochrane Centre, The Cochrane Collaboration, 2014.
Riechelmann 2007
Riechelmann RP, Krzyanowska MK, O’Carroll A,
Zimmermann C. Symptom and medication profiles among
cancer patients attending a palliative care clinic. Supportive
Care in Cancer 2007;15(12):1407–12.
Van den Beuken-van Everdingen 2007
Van den Beuken-van Everdingen MHJ, De Rijke JM,
Kessels AG, Schouten HC, van Kleef M, Patijn J. Prevalence
of pain in patients with cancer: a systematic review of the
past 40 years. Annals of Oncology 2007;18:1437–49.
Vyvey 2010
Vyvey M. Steroids as pain relief adjuvants. Canadian Family
Physician 2010;56(12):1295–7.
References to other published versions of this review
Hardy 2013
Hardy JR, Jenkins-Marsh S, Pinkerton E, Rickett K, Good
P. Corticosteroids for the management of cancer-related
pain in adults. Cochrane Database of Systematic Reviews
2013, Issue 10. [DOI: 10.1002/14651858.CD010756]
∗ Indicates the major publication for the study
17Corticosteroids for the management of cancer-related pain in adults (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Basile 2012
Methods Randomised controlled trial
Study duration: 3 months
Participants 20 consecutive patients (12 intervention, 8 control) with single-level vertebral neoplasm
or pathological fractures totally or partially refractory to analgesic treatment, with indi-
cation for vertebroplasty
Inclusion criteria:
• visual analogue scale (VAS, 0 to 10) pain score ≥ 5
• life expectancy ≥ 3 months
Interventions Intervention: intrasomatic injection of 4 mg/ml of dexamethasone phosphate through
vertebroplasty needle followed by cement injection (group A)
Control: standard vertebroplasty (group B)
Outcomes Pain intensity using VAS at various time intervals: 6 hours to 3 months
Notes Baseline VAS 8/10 in both groups. Greater reduction in VAS in group A at early time
points (including day 7), but no significant difference at last follow-up
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomly divided into 2 groups
Not specified how the random sequence
was generated
Allocation concealment (selection bias) Unclear risk Randomisation was obtained by blind ex-
traction of letters A or B in a closed enve-
lope
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk 3 interventional radiologists (all blinded to
treatment allocation)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No information provided
Incomplete outcome data (attrition bias)
All outcomes
Low risk 2 patients died in group A, 3 patients died
in group B during follow-up
Selective reporting (reporting bias) Low risk No problem detected
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Basile 2012 (Continued)
Other bias High risk Sample size: 20 participants; < 50 partici-
pants per treatment arm
Bruera 1985
Methods Prospective, randomised, double-blind, cross-over trial
Study duration: 14 days
Participants 40 terminally ill patients (in- and out-patients) with malignant disease
No specific anticancer treatment within 1 month
Oral analgesia according to individual requirements
Interventions 32 mg methylprednisolone (MP) daily (16 mg twice a day orally) or placebo for 5 days
Days 5 to 7: treatment-free
Days 8 to 12: cross-over to other arm then open label MP
Outcomes Pain intensity using VAS (0 to 100) assessed at days 0, 5, 13 and 33 (response defined
as > 30% improvement over placebo)
Anxiety
Daily oral analgesic consumption appetite
Food consumption (% of each meal)
Performance status
Activity score
Notes Pain one of several endpoints
Intensity of pain and daily consumption of analgesics was significantly lower after MP
compared with baseline or placebo
Depression, appetite and food consumption also improved on MP
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomly divided into 2 groups
Not specified how the random sequence
was generated
Allocation concealment (selection bias) Unclear risk Not specified
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not specified, same investigator did all eval-
uations
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Bruera 1985 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
High risk 9 patients did not complete the trial and
were not included in evaluation
3 patients reported no pain at baseline
Selective reporting (reporting bias) High risk Only 28 patients were evaluated for pain
Other bias High risk Sample size: 40 participants; < 50 partici-
pants per treatment arm
Bruera 2004
Methods Double-blind, parallel-arm trial
5 international centres
Study duration: 7 days
Participants 51 participants (25 intervention, 26 control) with advanced cancer and chronic nausea
(> 2 weeks) resulting from advanced cancer despite treatment with metoclopramide at a
minimal daily dose of 40 to 60 mg for 2 days
Interventions Intervention: 20 mg/day dexamethasone orally in addition to metoclopramide (60 mg/
day orally)
Control: placebo in addition to metoclopramide (60 mg/day)
Outcomes Pain, appetite, fatigue and nausea, measured on a 0 to 10 numerical rating scale (NRS)
(0 = symptom absent, 10 = worst possible symptom)
Quality of life: physical well-being, social well-being, functional well-being, emotional
well-being
Toxicity assessment: presence or absence of ankle oedema, insomnia, restlessness or other
symptoms (patient-rated)
Notes Pain secondary outcome measure. Nausea as primary endpoint
Pain intensity at baseline low in both arms. Authors therefore query meaningfulness of
pain as outcome measure
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised, method not specified
Allocation concealment (selection bias) Low risk Capsules containing both drugs identical
in appearance, randomisation in pharmacy
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind
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Bruera 2004 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blind
Incomplete outcome data (attrition bias)
All outcomes
Low risk 3 of 25 patients receiving dexamethasone
dropped out
5 of 26 patients receiving placebo dropped
out
Selective reporting (reporting bias) Low risk None detected
Other bias High risk Sample size: 51 participants; < 50 partici-
pants per treatment arm
Della 1989
Methods Double-blind, placebo-controlled, multi-centre study
Study duration: 8 weeks
Participants 403 participants (207 intervention, 196 control) with “pre-terminal” cancer
Inclusion criteria:
• pain, debility, cachexia, anorexia or other signs of advanced disseminated disease
• no longer candidates for aggressive anticancer therapy
• expected to survive ≥ 2 months
• no steroids within 1 month of study
Interventions Intervention: 125 mg/day IV methylprednisolone sodium succinate (MPSS) daily
Control: placebo (88.8 mg mannitol) daily IV for maximum of 8 weeks
Outcomes Linear Analogue Self-Assessment scale (LASA), 10 questions on pain, appetite, well-
being, nausea, sleepiness, weakness (10-point scale ranging from ’worst’ to ’best’)
Nurses Observation Scale for Inpatient Evaluation (NOSIE), 21 questions, 5-point scale
ranging from ’never’ to ’always’ (total score= 50 + social competence + social interest -
irritability - retardation - depression)
Notes Pain not primary outcome measure. Comparable LASA scores at baseline. MPSS pro-
duced significantly more improvement than placebo in LASA score for pain, appetite,
vomiting and well-being. Pain one of several endpoints
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation
scheme
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Della 1989 (Continued)
Allocation concealment (selection bias) Low risk Double-blind
Study medication was provided in blinded
packages that contained vials of either
MPSS or placebo
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind
Identity of the investigational therapy was
not known by the investigator, his staff or
the patients
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blind
Incomplete outcome data (attrition bias)
All outcomes
Low risk 30 MPSS-treated and 33-placebo treated
patients dropped out, 83 MPSS-treated
and 59-placebo treated patients died prior
to completing 8 weeks of treatment
Selective reporting (reporting bias) Low risk All outcomes reported
Other bias Unclear risk Sample size: 403 participants; 50 to 199
participants per treatment arm
Fossa 2001
Methods Randomised controlled trial
Study duration: 24 weeks
Participants 201 participants (101 prednisone, 100 flutamide) with castrate resistant prostate cancer
(CRPC) and symptomatic metastatic disease
Inclusion criteria:
• WHO performance status of 0 to 3 no previous use of prednisone
• flutamide or any other oral antiandrogen
• no previous systemic anticancer treatment, except the above primary hormonal
manipulation
Interventions Group F: 250 mg flutamide orally 3 times a day
Group P: 5 mg prednisone orally 4 times a day
Patients receiving LHRH analogues continued with this treatment
Outcomes Quality of life (QoL): QLQ C-30, a 30-item questionnaire assessing a range of physical,
emotional and social health issues
• all scales and single-item measures were linearly transformed to a 0 to 100 scale
• for function scale: higher score represents a higher level of function
• for symptom measures: a higher score corresponds to a worsening of symptoms.
Main endpoints were time to progression (TTP) and duration of survival
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Fossa 2001 (Continued)
Notes Pain not primary endpoint
Prednisone used as treatment of prostate cancer
Statistically significant treatment effects following prednisone were noted for pain, nau-
sea, vomiting and diarrhoea
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomisation method not described
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Flutamide 3 times a day, prednisone 4 times
a day, therefore no blinding possible
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated
Incomplete outcome data (attrition bias)
All outcomes
High risk Intention-to-treat
Patients had to remain in the trial for at least
6 weeks to be assessable for response. They
were otherwise included in the analysis as
’non-assessable’
Selective reporting (reporting bias) Unclear risk Not stated
Other bias Unclear risk Sample size: 201 participants; 50 to 199
participants per treatment arm
Graham 2006
Methods Pilot randomised controlled trial
8 recruiting centres
Study duration: 14 days
Participants 20 participants with malignant spinal cord compression (MSCC)
Inclusion criteria:
• malignant disease
• at least one of: pain, weakness, sensory symptoms, sphincter problems
• ECOG performance status ≥ 4 before the MSCC event
• minimum limb power 1/5
• estimated minimum survival of 2 months
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Graham 2006 (Continued)
Interventions High-dose: 96 mg dexamethasone intravenously day 0, continued to day 2 then weaned
to 0 by day 15
or
Low-dose: 16 mg dexamethasone intravenously day 0, continued to day 2 then weaned
to 0 by day 15
Radiotherapy in both arms
Outcomes Visual analogue pain score (0 to 10)
Toxicity (method not specified)
Survival
Ambulation and functional outcome (method not specified)
Notes High-dose versus low-dose dexamethasone study terminated because of inadequate re-
cruitment
No significant difference in pain in the first week
Analgesic use tended to be lower in high dose arm
Pilot study, not powered for outcome, descriptive analysis
Pain one of several endpoints
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Patients randomised via the Superdex web-
site
Allocation concealment (selection bias) Low risk Website protectedwith password unique to
each investigator
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Physicians were provided with patient’s as-
signed treatment
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Physicians were provided with patient’s as-
signed treatment
Incomplete outcome data (attrition bias)
All outcomes
High risk 4 out of 20 patients not evaluable
Selective reporting (reporting bias) Low risk None detected
Other bias High risk Sample size: 20 participants (pilot study);
< 50 participants per treatment arm
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Lauretti 2013
Methods Randomised, prospective, placebo-controlled trial
Study duration: 21 days
Participants 72 participants (6 groups of n = 12) with moderate/severe chronic cancer pain
Inclusion criteria:
• requiring around-the-clock opioid therapy
• all participants on amitriptyline 25 g daily and oral morphine
• VAS scale > 4/10 despite opioid therapy
Interventions Control group (CG): epidural 40 mg lidocaine diluted to 10 ml volume with N/saline
Dexamethasone group (DG): 40 mg lidocaine plus 10 mg dexamethasone
2.5 Met group: 2.5 mg epidural methadone with 40 mg lidocaine
5 Met group: 5 mg epidural methadone plus 40 mg lidocaine
7.5 Met group: 7.5 mg epidural methadone plus 40 mg lidocaine
7.5Met-Dex group: 7.5mgmethadone with 40mg lidocaine and 10 mg dexamethasone
All delivered as sacral block with free access to oral morphine to maintain VAS < 4/10
Outcomes Analgesic use, pain score (VAS), adverse effects
Assessed by patient daily diary
Notes Very small numbers in each group
Significantly less oral morphine consumption with dexamethasone
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation using a randomised num-
ber generator in a computer program
Allocation concealment (selection bias) Low risk Drugs were diluted in a 10 ml covered sy-
ringe in order to maintain blindness
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Same anaesthetist, unaware of the study
drug prepared by a second anaesthetist
Patients blind to treatment
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 4 patients from GC, 3 fromDG, 2 from 2.
5MetG, 2 from 5MetG, 2 from 7.5 MetG
and 1 from 7.5 MetDG were excluded due
to incomplete data collection
Minimum of 8 patients per group main-
tained for statistical purposes
Selective reporting (reporting bias) Low risk None detected
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Lauretti 2013 (Continued)
Other bias High risk Sample size: 72 participants; < 50 partici-
pants per treatment arm
Lee 2008
Methods Prospective, randomised, open-label study
Multi-site, international
Study duration: 42 weeks
Participants 598 participants (bortezomib 296, or dexamethasone 302) with relapsed multiple
myeloma
Interventions Bortezomib (B): 1.3 mg/m2, days 1, 4, 8 and 11 for eight 3-week cycles, then days 1, 8,
15 and 22 for three 5-week cycles IV bolus
Dexamethasone (D): 40 mg/day, days 1 to 4, 9 to 12 and 17 to 20 for four 5-week cycles,
then days 1 to 4 only for five 4-week cycles, oral
Outcomes Health-related quality of life (HRQL) (EORTCQLQ-C30), score range from 0 to 100;
higher scores reflect better quality of life, for symptom scale, higher scores reflect worse
symptoms
Functional Assessment of Cancer Therapy Neurotoxicity questionnaire (FACT/GOG-
NTX), 11 individual items evaluating symptoms of neurotoxicity on a scale of 0 (not at
all) to 4 (very much), items were reversed (reversed score = 4 - row score) therefore total
scores ranged from 0 to 44 with higher values indicating a lower burden of neurotoxicity
Questionnaires administered at baseline and 6-weekly to 42 weeks
Notes Health related QoL and toxicity assessed in patients participating in an efficacy study of
bortezomib versus dexamethasone in multiple myeloma
Pain not primary outcome measure
Benefit in pain scores in favour of B using available data but not when using imputed
data sets
Corticosteroids used as an anticancer treatment
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised (1:1)
Method not specified
Allocation concealment (selection bias) High risk Open-label
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Open-label
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Lee 2008 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Open-label
Incomplete outcome data (attrition bias)
All outcomes
High risk Amount of missing data increased over
time due to attrition related to adverse
events, disease progression, the premature
termination of the dexamethasone arm of
the study and death. Only 9% in the B
and 5% in the D arm completed proto-
col-specified treatment. Significantmissing
data with time
Selective reporting (reporting bias) Low risk None detected since pain not primary out-
come
Other bias Low risk Sample size: 598 participants; ≥ 200 par-
ticipants per treatment arm
Mercadante 2007
Methods Prospective, randomised, controlled study of steroids as adjuvant drugs to opioids
Study duration: 9 weeks
Participants 76 patients with advanced cancer (31 opioid, 35 dexamethasone) with pain requiring
strong opioids
Other co-analgesics allowed
Interventions Group O: conventional opioid treatment
Group OS: 8 mg dexamethasone orally along with conventional treatment
Outcomes Average daily pain intensity measured using the patient’s self report on NRS from 0
(absent) to 10 (maximum)
Well-being sensation, rated by means of a NRS from 0 to 10
Symptoms associated with opioid therapy or commonly present in advanced cancer
patients (nausea and vomiting, weakness, drowsiness, constipation, confusion), scale
from 0 to 3 (not at all, slight, a lot, awful)
Opioid escalation index percentage (OEI%) and absolute dose (OEI mg)
Notes No difference between groups in OEI
Other co-analgesics allowed, not standardised
Difference in OEI between arms at baseline
Risk of bias
Bias Authors’ judgement Support for judgement
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Mercadante 2007 (Continued)
Random sequence generation (selection
bias)
Unclear risk Patients randomly divided into 2 groups
Method not described
Allocation concealment (selection bias) High risk Method not stated
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Not stated
Incomplete outcome data (attrition bias)
All outcomes
High risk Half of the patients died before the third
week making the interpretation of any
long-term corticosteroid benefit difficult
Selective reporting (reporting bias) Unclear risk Authors did not specify the adverse drug
reactions where they claimed symptomatic
improvement except for nausea, vomiting
and constipation
Other bias High risk Sample size: 76 participants; < 50 partici-
pants per treatment arm
Paulsen 2014
Methods Randomised, placebo-controlled, double-blind, parallel-group, multi-centre, phase III
trial
Participants Patients with cancer experiencing pain > 4/10 receiving opioids
Interventions Methylprednisolone 16 mg or placebo 16 mg twice daily for 7 days
Outcomes Primary outcome: average pain intensity measured by BPI (0 to 10)
Secondary outcome:
• daily pain intensity at rest (ESAS 0 to 10)
• change in fatigue and appetite baseline to day 7 (EORTC-C30)
• adverse events
Notes 592 patients screened, 50 recruited over 3 to 4-year time period
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computerised randomisation conducted
independently
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Paulsen 2014 (Continued)
Allocation concealment (selection bias) Low risk Methylprednisolone and placebo capsules
were identical in appearance
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk All parties blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Randomisation was blinded for all parties
until the completion of data collection
Incomplete outcome data (attrition bias)
All outcomes
Low risk 1 patient died in the placebo group and
1 patient withdrew from the intervention
group as a result of malignant bowel ob-
struction; none lost to follow-up
ITT analysis
Selective reporting (reporting bias) Low risk All outcomes reported
Other bias High risk Sample size: 50 participants; < 50 partici-
pants per treatment arm
Popiela 1989
Methods Randomised, prospective, double-blind, placebo-controlled, multi-site clinical trial
Study duration: 8 weeks
Participants 173 female participants (85 intervention, 88 control) with advanced, terminal cancer
and symptoms (pain, debility, nausea, cachexia etc)
Interventions Intervention: 125 mg infusion of methylprednisolone sodium succinate (MPSS) IV
Control: matching placebo (P)
Both for 56 consecutive days
Outcomes Linear Analogue Self-Assessment scale (LASA), patient ratings for pain, appetite, sense
of well-being completed weekly x 8 weeks
Mortality
Concomitant medications
Adverse events
Notes No significant changes with time for pain or sleep
No significant changes in opioid use
Better overall LASA score for patients on MPSS
Risk of bias
Bias Authors’ judgement Support for judgement
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Popiela 1989 (Continued)
Random sequence generation (selection
bias)
Low risk Randomisation specified by a computer-
generated randomisation scheme
Allocation concealment (selection bias) Low risk Double-blind
Study medication was provided in blinded
packages containing vials of either placebo
or MPSS
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blind, data from 2 sites removed
(“significant investigator interaction”)
Incomplete outcome data (attrition bias)
All outcomes
Low risk 38% MPSS and 30% P died before study
completion
ITT analysis
Selective reporting (reporting bias) Low risk All outcomes reported
Other bias Unclear risk Sample size: 173 participants; 50 to 199
participants per treatment arm
Teshima 1996
Methods Multi-site, prospective randomised controlled trial of RT alone or RT and methylpred-
nisolone for bone metastases
Study duration: 14 days
Participants 38 participants (20 intervention, 18 control) with bonemetastases and clinical symptoms
such as pain, loss of appetite, general fatigue, sleep disturbance, anxiety, depression and
nausea and/or vomiting
Interventions Intervention: radiation combined with methylprednisolone 500 g IV daily x 3 days
Control: radiation alone
Outcomes RTOG pain score plus QoL (1 to 10), patient scored
Performance status
Urinary hydroxyproline/creatinine ratio
Serum tartrate-resistance acid phosphatase (tumour marker)
Notes Pain not only endpoint
No difference between groups with respect to pain
Risk of bias
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Teshima 1996 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomly allocated to 1of the 2 treatments
according to Peto’s balanced randomised
list
Allocation concealment (selection bias) Unclear risk Not specified
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No placebo, no blinding
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No placebo, no blinding
Incomplete outcome data (attrition bias)
All outcomes
Low risk No dropouts declared
Selective reporting (reporting bias) High risk Graphical presentation of pain scores and
no mention of adverse events
Other bias High risk Sample size: 38 participants; < 50 partici-
pants per treatment arm
Twycross 1985
Methods Double-blind, randomised, placebo-controlled trial
Study duration: 7 days
Participants 27 participants (16 intervention, 11 control) with cancer of the breast or lung
Interventions Intervention: 5 mg prednisolone by mouth 3 times a day
Control: placebo of identical appearance
Outcomes Visual analogue scales (VAS), 100 mm, relating to pain, nausea, mood, sleep, alertness
and strength
Notes Poor quality RCT, no standard background dosing, changes in adjunct medication “kept
to a minimum”
Analgesics adjusted as required
Difference in pain scales at baseline
No significant difference at day 8
Risk of bias
Bias Authors’ judgement Support for judgement
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Twycross 1985 (Continued)
Random sequence generation (selection
bias)
Unclear risk Randomised
Method not specified
Allocation concealment (selection bias) Unclear risk 266 potentially eligible, only 56 ran-
domised
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk 266 screened, 56 entered
Double-blind
Placebo of identical appearance
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blind
Incomplete outcome data (attrition bias)
All outcomes
High risk Only 27/56 completed outcome assess-
ments
Selective reporting (reporting bias) Low risk All outcomes reported
Other bias High risk Sample size: 27 participants; < 50 partici-
pants per treatment arm
Vecht 1989
Methods Randomised, multi-centre controlled trial
Study duration: 1 week
Participants 37 participants (22 high-dose, 15 low-dose) with metastatic spinal cord compression
(SCC)
Interventions High-dose: 100 mg dexamethasone dissolved in glycerol and water
Low-dose: 10 mg dexamethasone dissolved in glycerol and water, both delivered imme-
diately following diagnosis of SCC by myelography
Outcomes NRS for pain (0 to 10)
Ambulatory status (grade 1, walking independently - grade 5, no power in legs)
Bladder function
Notes High-dose versus low-dose dexamethasone plus radiotherapy for SCC
No difference seen in pain, ambulation or bladder function
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomised
Not specified how the random sequence
was generated
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Vecht 1989 (Continued)
22 patients received high-dose and 15 low-
dose (no explanation given)
Allocation concealment (selection bias) Low risk Coded ampoules blindly administered
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Code broken by statistician at final analysis
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Code broken by statistician at final analysis
Incomplete outcome data (attrition bias)
All outcomes
Low risk 40 patients randomised, 3 had insufficient
data for analysis
Selective reporting (reporting bias) Low risk None detected
Other bias High risk Sample size: 37 participants; < 50 partici-
pants per treatment arm
Yennurajalingam 2013
Methods Randomised, double-blind, placebo-controlled trial
Study duration: 14 days
Participants 120 participants (62 intervention, 58 control) with advanced cancer and ≥ 3 symptoms
during the previous 24 hours (e.g. pain, fatigue, chronic nausea cluster) with average
intensity of ≥ 4 on the Edmonton Symptom Assessment Scale (ESAS)
Interventions Intervention: 4 mg dexamethasone orally twice per day for 14 days
Control: placebo orally twice per day for 14 days
Outcomes ESAS to assess severity of common symptoms (e.g. pain, fatigue, nausea, depression,
anxiety) rated on a NRS of 0 to 10 (0 = no symptoms, 10 = worst possible severity)
Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), 27 questions,
scale 0 to 4 (0 = not at all, 4 = very much)
Functional Assessment of Cancer Therapy-Anorexia-Cachexia (FAACT), 12-item symp-
tom-specific subscale, scale 0 to 4
Hospital Anxiety and Depression Scale (HADS), 14-item questionnaire
Notes Fatigue was primary outcome measure
Pain as measured by ESAS significantly better on dexamethasone at day 8, but not day
15
Risk of bias
Bias Authors’ judgement Support for judgement
33Corticosteroids for the management of cancer-related pain in adults (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Yennurajalingam 2013 (Continued)
Random sequence generation (selection
bias)
Unclear risk Randomisation method not described
Allocation concealment (selection bias) Unclear risk Not stated
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk All members of the research team except
the investigational pharmacist and statisti-
cian were blinded to treatment assignment
throughout the study
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk All members of the research team except
the investigational pharmacist and statisti-
cian were blinded to treatment assignment
throughout the study
Incomplete outcome data (attrition bias)
All outcomes
High risk 19 of 62 patients receiving dexamethasone
were not evaluable
17 of 58 patients receiving placebo were
not evaluable
Selective reporting (reporting bias) Low risk None detected
Other bias Unclear risk Sample size: 120 participants; 50 to 199
participants per treatment arm
BPI: Brief Pain Inventory
ECOG: Eastern Cooperative Oncology Group
ESAS: Edmonton Symptom Assessment Scale
ITT: intention-to-treat
IV: intravenous
LASA: Linear Analogue Self-Assessment scale
LHRH: Luteinizing Hormone Releasing Hormone
MP: methylprednisolone
MPSS: methylprednisolone sodium succinate
MSCC: malignant spinal cord compression
NRS: numerical rating scale
OEI: opioid escalation index
P: placebo
QoL: quality of life
RCT: randomised controlled trial
RT: radiation
RTOG: Radiation Therapy Oncology Group
SCC: spinal cord compression
VAS: visual analogue scale
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Campio 1983 Abstract only; pain not an outcome measure
Chanan-Khan 2011 2 arms not identical; measuring tumour flare reaction (TFR) of which pain is primary feature, more a
measure of TFR
Coloma 2001 Postoperative pain rather than cancer pain
Datta 1997 Not all patients had pain at baseline
Dutta 2012 Prophylactic steroids; primary endpoint was skin toxicity, not pain
Friedenberg 1991 Not randomised; toxicity assessments included
Fuccio 2011 Prophylactic steroids; pain not specifically measured
Gomez-Hernandez 2010 Prevention of postoperative pain
Hird 2009 Non-randomised; no toxicity assessment
Laval 2000 Trial underpowered; focus on resolution of bowel obstruction and symptoms
North 2003 Quality of life not pain as an outcome measure
Richardson 2009 Pain not assessed
Richardson 2010 Phase 1/2 trial; pain not an endpoint
Richardson 2011 Pain not an endpoint
Richardson 2012 Pain not assessed
Rinehart 2010 Pain not an endpoint
Rizzo 2009 No detailed results
Sanguineti 2003 Assessed post-radiation toxicity, not pain
Schmuth 2002 Pain not assessed
Tantawy 2008 Postoperative pain after oncologic pelvic surgery
Tong 1982 Patients not treated with corticosteroids
Vecht 1994 Pain not an endpoint
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(Continued)
Vij 2012 Pain not an endpoint
Yennurajalingam 2010 Abstract only
Yennurajalingam 2012 Abstract only
Yoshioka 2011 Pain not an endpoint
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D A T A A N D A N A L Y S E S
Comparison 1. Pain
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Pain at 1 week 6 315 Mean Difference (IV, Random, 95% CI) -0.84 [-1.38, -0.30]
Analysis 1.1. Comparison 1 Pain, Outcome 1 Pain at 1 week.
Review: Corticosteroids for the management of cancer-related pain in adults
Comparison: 1 Pain
Outcome: 1 Pain at 1 week
Study or subgroup Drug Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Basile 2012 12 1.5 (0.7) 8 2.9 (0.6) 26.1 % -1.40 [ -1.97, -0.83 ]
Bruera 1985 28 3.68 (1.4) 28 5.01 (1.5) 21.4 % -1.33 [ -2.09, -0.57 ]
Yennurajalingam 2013 43 3.95 (2.89) 41 5.01 (2.8) 12.9 % -1.06 [ -2.28, 0.16 ]
Bruera 2004 22 2.4 (3.4) 21 2.8 (3.6) 5.7 % -0.40 [ -2.50, 1.70 ]
Mercadante 2007 34 3.1 (1.9) 31 3.2 (1.9) 17.8 % -0.10 [ -1.02, 0.82 ]
Paulsen 2014 25 3.6 (1.96) 22 3.68 (1.56) 16.2 % -0.08 [ -1.09, 0.93 ]
Total (95% CI) 164 151 100.0 % -0.84 [ -1.38, -0.30 ]
Heterogeneity: Tau2 = 0.21; Chi2 = 9.72, df = 5 (P = 0.08); I2 =49%
Test for overall effect: Z = 3.03 (P = 0.0024)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
Favours corticosteroid Favours placebo/control
37Corticosteroids for the management of cancer-related pain in adults (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
A D D I T I O N A L T A B L E S
Table 1. Comparison of included studies
Comparison Number of studies References
Dexamethasone - standard therapy 5 Basile 2012; Lauretti 2013; Lee 2008; Mercadante 2007; Teshima
1996
(Methyl-)prednisolone - placebo 5 Bruera 1985; Della 1989; Paulsen 2014; Popiela 1989; Twycross
1985
Dexamethasone - placebo 2 Bruera 2004; Yennurajalingam 2013
High-dose versus low-dose dexamethasone 2 Graham 2006; Vecht 1989
Prednisone - flutamide 1 Fossa 2001
Table 2. Primary sites of disease
Breast Lung Prostate Ovary Gastroin-
testinal
Genitouri-
nary
Uterus Other Not specified
Basile
2012
x x
Bruera
1985
x x x x x
Bruera
2004
x x x x x
Della 1989 x x x x x x
Fossa 2001 x
Graham
2006
x x x x x
Lauretti
2013
x x x x x
Lee 2008 x
Mer-
cadante
2007
x
Paulsen
2014
x x x x x
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Table 2. Primary sites of disease (Continued)
Popiela
1989
x
Teshima
1996
x
Twycross
1985
x x
Vecht
1989
x
Yennura-
jalingam
2013
x x x x x x
Table 3. Target population, drug and dose of the 15 included studies
Study Target population Drug Dose
Basile 2012 Bone neoplasm Dexamethasone 4 mg/mL
Bruera 1985 Advanced cancer Methylprednisolone 32 mg
Bruera 2004 Advanced cancer Dexamethasone 20 mg
Della 1989 Advanced cancer Methylprednisolone 125 mg
Fossa 2001 Prostate cancer Prednisone 20 mg
Graham 2006 Malignant spinal cord compres-
sion
Dexamethasone 16 mg
Graham 2006 Malignant spinal cord compres-
sion
Dexamethasone 96 mg
Lauretti 2013 Advanced cancer Dexamethasone 10 mg
Lee 2008 Multiple myeloma Dexamethasone 40 mg
Mercadante 2007 Adjuvant drug in advanced cancer
patients
Dexamethasone 8 mg
Paulsen 2014 Advanced cancer Methylprednisolone 16 mg
Popiela 1989 Advanced cancer Methylprednisolone 125 mg
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Table 3. Target population, drug and dose of the 15 included studies (Continued)
Teshima 1996 Bone metastases Methylprednisolone 500 mg
Twycross 1985 Breast or bronchus cancer Prednisolone 15 mg
Vecht 1989 Advanced cancer Dexamethasone 10 mg
Vecht 1989 Advanced cancer Dexamethasone 100 mg
Yennurajalingam 2013 Advanced cancer Dexamethasone 8 mg
A P P E N D I C E S
Appendix 1. MEDLINE search strategy
1. exp Adrenal Cortex Hormones/
2. (corticoid* or corticosteroid* or glucocorticoid*).tw.
3. (adrenal adj2 hormone*).tw.
4. Betamethasone/
5. betamethasone.tw.
6. Fludrocortisone/
7. fludrocortisone.tw.
8. Cortisone/
9. (cortisone acetate or cortisone).tw.
10. deflazacort.tw.
11. Dexamethasone/
12. dexamethasone.tw.
13. Hydrocortisone/
14. hydrocortisone.tw.
15. Methylprednisolone/
16. methylprednisolone.tw.
17. Prednisolone/
18. prednisolone.tw.
19. Triamcinolone/
20. triamcinolone.tw.
21. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20
22. exp Pain/
23. pain.tw.
24. Pain Measurement/
25. exp Analgesics/
26. exp Analgesia/
27. “analges*”.tw.
28. (quality adj2 life).tw.
29. quality of life/
30. 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29
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31. malignant.tw.
32. malignancy.tw.
33. “tumor*”.tw.
34. “tumour*”.tw.
35. “cancer*”.tw.
36. “carcinoma*”.tw.
37. exp Neoplasms/
38. 31 or 32 or 33 or 34 or 35 or 36 or 37
39. 21 and 30 and 38
40. randomized controlled trial.pt.
41. controlled clinical trial.pt.
42. randomized.ab.
43. randomised.ab.
44. placebo.ab.
45. drug therapy.fs.
46. randomly.ab.
47. trial.ab.
48. groups.ab.
49. 40 or 41 or 42 or 43 or 44 or 45 or 46 or 47
50. exp animals/ not humans.sh.
51. 49 not 50
52. 39 and 51
Appendix 2. MEDLINE (in-process & other non-indexed citations)
1. (corticoid* or corticosteroid* or cortisone or betamethasone or deflazacort or dexamethasone or hydrocortisone ormethylprednisolone
or prednisolone or triamcinolone or fludrocortisone).mp. [mp=title, abstract, original title, name of substance word, subject heading
word, keyword heading word, protocol supplementary concept, rare disease supplementary concept, unique identifier]
2. (pain or analges* or “quality of life”).mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword
heading word, protocol supplementary concept, rare disease supplementary concept, unique identifier]
3. (malignan* or cancer* or carcinoma* or neoplas*).mp. [mp=title, abstract, original title, name of substance word, subject heading
word, keyword heading word, protocol supplementary concept, rare disease supplementary concept, unique identifier]
4. 1 and 2 and 3
5. 1 and 3
6. ((pain or analges* or quality adj3 life).mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword
heading word, protocol supplementary concept, rare disease supplementary concept, unique identifier]
7. 5 and 6
Appendix 3. EMBASE search strategy
1. exp corticosteroid/
2. betamethasone.ti,ab.
3. cortisone.ti,ab.
4. deflazacort.ti,ab.
5. dexamethasone.ti,ab.
6. fludrocortisone.ti,ab.
7. hydrocortisone.ti,ab.
8. methylprednisolone.ti,ab.
9. prednisolone.ti,ab.
10. triamcinolone.ti,ab.
11. (corticoid* OR corticosteroid* OR glucocorticoid*).ti,ab.
12. 1 or 2 or 3 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11
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13. exp pain/
14. pain assessment/
15. exp analgesic agent/
16. exp analgesia/
17. pain.ti,ab.
18. “analges*”.ti,ab.
19. (quality adj2 life).ti,ab.
20. 13 or 14 or 15 or 16 or 17 or 18 or 19
21. malignant.ti,ab.
22. malignancy.ti,ab.
23. “carcinoma$”.ti,ab.
24. “cancer$”.ti,ab.
25. “tumo*r$”.ti,ab.
26. exp neoplasm/
27. 21 or 22 or 23 or 24 or 25 or 26
28. 12 and 20 and 27
29. Clinical trial/
30. Randomized controlled trial/
31. Randomization/
32. Single blind procedure/
33. Double blind procedure/
34. Crossover procedure/
35. Placebo/
36. (randomised or randomized or placebo or randomly or trial or groups).ti,ab.
37. 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36
38. animal/
39. human/
40. 37 not (37 and 38)
41. 37 not 40
42. 28 not 41
Appendix 4. CENTRAL search strategy
#1 MeSH descriptor [Adrenal Cortex Hormones] explode all trees
#2 (corticoid* or corticosteroid* or glucocorticoid*):ti,ab,kw
#3 (betamethasone or fludrocortisone or cortisone or deflazacort or dexamethasone or hydrocortisone or methylprednisolone or
prednisolone or triamcinolone):ti,ab,kw
#4 (#1 OR #2 OR #3)
#5 MeSH descriptor [ Pain] explode all trees
#6 MeSH descriptor [Pain Measurement] this term only
#7 MeSH descriptor [Analgeia] explode all trees
#8 MeSH descriptor [Analgesics] explode all trees
#9 MeSH descriptor [Quality of Life] this term only
#10 (pain or analges* or Quality near/3 Life):ti,ab,kw
#11 (#5 OR #6 OR #7 OR #8 OR #9 OR #10)
#12 (malignan* OR malignancy OR tumor* OR tumour* OR cancer* OR carcinoma*):ti,ab,kw
#13 MeSH descriptor [Neoplasms] explode all trees
#14 (#12 OR #1)
#15 (#4 AND #11 AND #14)
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
We updated the methods of the review to include the GRADE approach to assess the overall quality of the evidence for the primary
outcome. There were insufficient data to evaluate different subgroups for this review, however we will perform subgroup analysis in
any updated versions of this review. We will perform intention-to-treat analysis where possible in future updates.
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